CN108883109A - 用于治疗急性髓性白血病的联合疗法 - Google Patents

用于治疗急性髓性白血病的联合疗法 Download PDF

Info

Publication number
CN108883109A
CN108883109A CN201780021735.4A CN201780021735A CN108883109A CN 108883109 A CN108883109 A CN 108883109A CN 201780021735 A CN201780021735 A CN 201780021735A CN 108883109 A CN108883109 A CN 108883109A
Authority
CN
China
Prior art keywords
amino
salt
base
pyrazine
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780021735.4A
Other languages
English (en)
Chinese (zh)
Inventor
埃尔库特·巴赫切吉
山木阳子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of CN108883109A publication Critical patent/CN108883109A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780021735.4A 2016-03-29 2017-03-27 用于治疗急性髓性白血病的联合疗法 Pending CN108883109A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662314700P 2016-03-29 2016-03-29
US62/314700 2016-03-29
US201662368343P 2016-07-29 2016-07-29
US62/368343 2016-07-29
PCT/JP2017/012293 WO2017170348A1 (en) 2016-03-29 2017-03-27 Combination therapy for the treatment of acute myeloid leukemia

Publications (1)

Publication Number Publication Date
CN108883109A true CN108883109A (zh) 2018-11-23

Family

ID=59965623

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780021735.4A Pending CN108883109A (zh) 2016-03-29 2017-03-27 用于治疗急性髓性白血病的联合疗法

Country Status (10)

Country Link
US (2) US20190117649A1 (enExample)
EP (1) EP3436014A4 (enExample)
JP (1) JP2019512495A (enExample)
KR (1) KR20180124055A (enExample)
CN (1) CN108883109A (enExample)
BR (1) BR112018069111A2 (enExample)
CA (1) CA3018155A1 (enExample)
MX (1) MX2018011975A (enExample)
RU (1) RU2018134167A (enExample)
WO (1) WO2017170348A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490497A (zh) * 2019-02-22 2021-10-08 韩美药品株式会社 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物
CN114728004A (zh) * 2019-10-14 2022-07-08 阿斯利康(瑞典)有限公司 用于治疗恶性血液病的组合疗法
CN114828842A (zh) * 2019-10-21 2022-07-29 理森制药股份公司 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
US12325698B2 (en) 2018-07-25 2025-06-10 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
US12350265B2 (en) 2019-06-27 2025-07-08 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
US12433867B2 (en) 2019-02-22 2025-10-07 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
PL3949952T3 (pl) 2019-04-03 2024-10-14 Astellas Pharma Inc. Kompozycja farmaceutyczna
JP2025502748A (ja) 2021-12-30 2025-01-28 バイオメア フュージョン，インコーポレイテッド Ｆｌｔ３の阻害剤としてのピラジン化合物
KR102559124B1 (ko) 2022-08-25 2023-07-26 주식회사 엔젠바이오 Flt3 유전자 증폭용 조성물 및 이의 용도

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12325698B2 (en) 2018-07-25 2025-06-10 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
CN113490497A (zh) * 2019-02-22 2021-10-08 韩美药品株式会社 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物
CN113490497B (zh) * 2019-02-22 2025-04-04 韩美药品株式会社 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物
US12433867B2 (en) 2019-02-22 2025-10-07 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
US12350265B2 (en) 2019-06-27 2025-07-08 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
CN114728004A (zh) * 2019-10-14 2022-07-08 阿斯利康(瑞典)有限公司 用于治疗恶性血液病的组合疗法
CN114828842A (zh) * 2019-10-21 2022-07-29 理森制药股份公司 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物

Also Published As

Publication number Publication date
CA3018155A1 (en) 2017-10-05
EP3436014A1 (en) 2019-02-06
KR20180124055A (ko) 2018-11-20
US20190117649A1 (en) 2019-04-25
BR112018069111A2 (pt) 2019-03-19
EP3436014A4 (en) 2019-11-27
RU2018134167A3 (enExample) 2020-06-30
WO2017170348A1 (en) 2017-10-05
US20200360372A1 (en) 2020-11-19
RU2018134167A (ru) 2020-04-29
JP2019512495A (ja) 2019-05-16
MX2018011975A (es) 2019-01-15

Similar Documents

Publication Publication Date Title
CN108883109A (zh) 用于治疗急性髓性白血病的联合疗法
Andersson et al. Clofarabine±fludarabine with once daily iv busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS
KR20220024639A (ko) 백혈병 또는 골수이형성 증후군을 치료하기 위한 베네토클락스, 길테리티닙, 미도스타우린 또는 다른 화합물과 조합된 아자시티딘
JP2009102408A (ja) ホモハリングトニンを単独で、または他の薬剤と組み合わせて用いる、ｓｔｉ５７１に耐性または不耐性の慢性骨髄性白血病の治療
TWI759316B (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
Davids et al. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Samarkandi et al. Evaluation of eltrombopag in thrombocytopenia post hematopoietic cell transplantation: rertrospective observational trial
US20230026808A1 (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
KR20160113302A (ko) 호중구감소증을 치료하기 위한 조성물 및 방법
JP2021063014A (ja) 白血病治療薬
Nelson et al. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer
KR102505218B1 (ko) BCL-2 억제제와 MCl-1 억제제의 조합물, 이의 용도 및 약학적 조성물
WO2020103788A1 (zh) 西达本胺联合r-chop的应用及联合药物
JP2020524681A (ja) 血液ガンのためのｍｃｌ−１阻害剤と標準治療処置との組み合わせ、その使用及び医薬組成物
CN116390735A (zh) 治疗癌症的Bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物
CN111228264A (zh) 西达本胺联合cgb以及自体造血干细胞的应用及联合药物
WO2021079129A1 (en) Dosing regimen
JP2012025734A (ja) 骨髄異形性症候群を治療するための組成物および方法
Loaiza-Bonilla et al. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents
Shinde et al. Cardiotoxicity in Contemporary Treatments: New Issues, Mechanisms, and Preventive Techniques
KR102199253B1 (ko) 만성 골수성 백혈병을 치료 또는 관해하기 위한 의약 조성물
Patel et al. Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study
HK40092504A (zh) 治疗癌症的bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物
CN100364607C (zh) 化合物ps-341在制备治疗慢性粒细胞性白血病的药物中的应用
HK40106881A (zh) 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181123